<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Therapy for metastatic colorectal cancer in older adult patients and those with a poor performance status
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Therapy for metastatic colorectal cancer in older adult patients and those with a poor performance status
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Therapy for metastatic colorectal cancer in older adult patients and those with a poor performance status
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Hanna K Sanoff, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard M Goldberg, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 25, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Colorectal cancer (CRC) is a leading cause of cancer-related death in the United States and other developed countries. The incidence of CRC steadily increases with age. Nearly 60 percent of cases develop over the age of 65; 30 percent are 75 years or older [
         <a href="#rid1">
          1
         </a>
         ]. The United States Census Bureau projects that by the year 2030, the number of Americans over age 65 make up 21 percent of the population (compared with 15 percent at present) [
         <a href="#rid2">
          2
         </a>
         ]. As a result, the number of patients over the age of 70 presenting for CRC care is expected to rise.
        </p>
        <p>
         Although some patients with metastatic CRC (mCRC) are potentially resectable for cure (particularly those with isolated liver metastases), treatment for most patients is palliative and generally consists of systemic chemotherapy. Multiple chemotherapy agents (
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         ,
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         ,
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         , and
         <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">
          trifluridine-tipiracil
         </a>
         ), multiple molecularly targeted agents (
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">
          aflibercept
         </a>
         ,
         <a class="drug drug_general" data-topicid="94963" href="/z/d/drug information/94963.html" rel="external">
          ramucirumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         , and
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         ), and the oral multikinase inhibitor
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         are approved for use in advanced CRC. Most recently, immune checkpoint inhibitors have been approved for treatment of advanced microsatellite instability-high or deficient mismatch repair mCRC in the first-line setting.
        </p>
        <p>
         This topic review will cover issues related to selection of systemic therapy for nonresectable mCRC in older adult patients and those with a poor performance status (PS). General principles of chemotherapy treatment for mCRC, specific treatment recommendations for initial therapy, and the approach to later lines of systemic therapy for non-older adult patients are presented elsewhere, as is adjuvant chemotherapy for older adult patients with colon cancer and the management of potentially resectable CRC liver and lung metastases. (See
         <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">
          "Systemic therapy for metastatic colorectal cancer: General principles"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2508.html" rel="external">
          "Adjuvant therapy for resected colon cancer in older adult patients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2796.html" rel="external">
          "Surgical resection of pulmonary metastases: Outcomes by histology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7815.html" rel="external">
          "Surgical resection of pulmonary metastases: Benefits, indications, preoperative evaluation, and techniques"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CHALLENGES SPECIFIC TO OLDER ADULTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The essential principles of treating mCRC in older adults are the same as in younger patients. However, in older patients, who may have age-related organ function decline and medical comorbidity, special attention must be paid to the risks of systemic therapy (both treatment-related toxicity and quality of life [QOL] issues), particularly in the context of estimated life expectancy. Age-related organ function changes that are relevant to the treatment of patients with CRC are outlined in the table  (
         <a class="graphic graphic_table graphicRef57349" href="/z/d/graphic/57349.html" rel="external">
          table 1
         </a>
         ). A thorough discussion of the age-related changes that should be considered when assessing the risk of systemic chemotherapy for mCRC is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2823.html" rel="external">
          "Systemic chemotherapy for cancer in older adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Quality of life issues
         </span>
         <span class="headingEndMark">
          —
         </span>
         QOL is a crucial component of decision-making when treating older patients. The available data suggest that older patients are just as willing to try chemotherapy as their younger counterparts, but less willing to endure severe treatment-related side effects.
        </p>
        <p>
         There are few data about how chemotherapy affects QOL in older patients with mCRC [
         <a href="#rid3">
          3,4
         </a>
         ]. A major issue is whether the higher response rates and generally longer survival seen with modern combination regimens (as compared with a strategy of sequential single agents) are outweighed by the greater likelihood of side effects and adverse impact on QOL. In one of the only trials to address this issue, the MRC FOCUS2 trial, 459 patients who were considered unfit for full-dose chemotherapy because of advanced age alone (29 percent), frailty (32 percent), or both (38 percent) were randomly assigned, using a 2x2 factorial design, to short-term infusional
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         (FU) plus
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         with or without
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         , or
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         with or without oxaliplatin [
         <a href="#rid4">
          4
         </a>
         ]. The median age was 74, with 43 percent of patients older than 75, and 13 percent older than 80 years of age; 29 percent had a PS of 2  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         The following findings were noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the factorial comparison, the addition of
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         to either fluoropyrimidine was associated with significantly higher response rates and a trend toward better progression-free and overall survival (OS) that was not statistically significant. However, the use of oxaliplatin had a detrimental impact on QOL, with significantly fewer patients reporting improved global QOL at week 12 to 14 (49 versus 62 percent, p = 0.04).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         QOL improvement was the primary outcome measure for the comparison of
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         versus short-term infusional FU plus
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         . Rates of improved global QOL at 12 to 14 weeks were the same in both groups (56 percent), despite more treatment-related side effects with capecitabine.
        </p>
        <p>
        </p>
        <p>
         This study is described in more detail below. (See
         <a class="local">
          'Reduced dose FOLFOX or XELOX'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Measures of physical function and reserve
         </span>
         <span class="headingEndMark">
          —
         </span>
         Age-related changes in physical health vary widely among individuals. Chronological age is a poor marker of a patient's functional status. Several methods of functional assessment are available, several of which are used in the Comprehensive Geriatric Assessment (CGA).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Performance status
         </strong>
         – The most common method to measure physiologic reserve and functional status in cancer patients is the clinician estimated PS. There are three widely used scales, the Eastern Cooperative Oncology Group (ECOG) scale  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 2
         </a>
         ), the Karnofsky Performance Status (KPS)  (
         <a class="graphic graphic_table graphicRef58785" href="/z/d/graphic/58785.html" rel="external">
          table 3
         </a>
         ), and the
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.npcrc.org%2Ffiles%2Fnews%2Fpalliative_performance_scale_PPSv2.pdf&amp;token=7glf2xtn3A0YC%2FXhi1Ue2yu5qd58vttW8oVUyVpANVYhy2lgKfO1EWeT6Kru8iCahkVdQSNtVVi%2Bq5OXXLSJUoOa96FpJMRjdEro%2BVruVjI%3D&amp;TOPIC_ID=2512" target="_blank">
          Palliative Prognostic Scale (PPS)
         </a>
         , which includes information about self-care, oral intake, physical activity, disease extent, and level of consciousness and has been found to have similar predictive accuracy for survival as the KPS. (See
         <a class="medical medical_review" href="/z/d/html/2206.html" rel="external">
          "Survival estimates in advanced terminal cancer", section on 'Performance status'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These performance scales are useful to assess a patient's ability to tolerate chemotherapy and to assess short-term prognosis. Regardless of age, patients with a poor PS (eg, ECOG PS &gt;2, KPS or PPS &lt;60) usually tolerate chemotherapy poorly and have a short median OS. However, PS tends to underrepresent the degree of functional impairment in the older patient. (See
         <a class="medical medical_review" href="/z/d/html/2823.html" rel="external">
          "Systemic chemotherapy for cancer in older adults", section on 'Assessments of physical function and reserve'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Studies addressing management of patients with mCRC and a poor PS (who may not necessarily be older adults) are presented below.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ADL and IADL scales
         </strong>
         – A more comprehensive understanding of an older patient's functional state can be obtained by use of Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) scales. ADL refers to the skills that are necessary for basic living, and include feeding, grooming, transferring, and toileting. IADL refers to the skills required to live independently in the community, including shopping, managing finances, housekeeping, preparing meals, and the ability to take medications.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2237205305">
         <span class="h2">
          The comprehensive geriatric assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Assessment of functional status the ADL and IADL scales is a component of the CGA. Randomized trials have shown that CGA-driven interventions can improve patient and caregiver satisfaction with communication about aging-related concerns and satisfaction with overall care, reduce chemotherapy toxicity, reduce falls during cancer treatment, increase advance directive completion, and for patients with CRC improve completion of scheduled chemotherapy. (See
         <a class="medical medical_review" href="/z/d/html/2808.html" rel="external">
          "Comprehensive geriatric assessment for patients with cancer", section on 'Potential benefits'
         </a>
         .)
        </p>
        <p>
         Incorporating a more thorough geriatric assessment of function using the CGA can aid treatment decision-making in older cancer patients. American Society of Clinical Oncology (ASCO) guidelines recommend that a geriatric assessment be undertaken in all patients age 65 and older who are receiving chemotherapy, and we agree with this approach [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2808.html" rel="external">
          "Comprehensive geriatric assessment for patients with cancer", section on 'Who needs a CGA?'
         </a>
         .)
        </p>
        <p>
         There is no uniform CGA measurement tool. The ASCO guidelines provide a minimum dataset for practical assessment of vulnerabilities in older patients with cancer  (
         <a class="graphic graphic_table graphicRef118720" href="/z/d/graphic/118720.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ]. The guidelines also include recommendations for specific interventions guided by the geriatric assessment  (
         <a class="graphic graphic_table graphicRef118298" href="/z/d/graphic/118298.html" rel="external">
          table 5
         </a>
         ). This subject is discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2808.html" rel="external">
          "Comprehensive geriatric assessment for patients with cancer", section on 'Domains of a CGA'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2808.html" rel="external">
          "Comprehensive geriatric assessment for patients with cancer", section on 'Obtaining patient data'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Guiding treatment decisions by assessment of physical function
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is general agreement that frail older adults, those with significant functional impairment, or an ECOG PS of 3 to 4  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 2
         </a>
         ), should be supported with palliative measures aimed at maintaining QOL [
         <a href="#rid6">
          6
         </a>
         ]. There is also general agreement that active, fit, older patients without comorbidity should be treated in the same fashion as younger patients with mCRC  (
         <a class="graphic graphic_table graphicRef68620" href="/z/d/graphic/68620.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="local">
          'Frail, significant functional impairment, poor performance status'
         </a>
         below and
         <a class="local">
          'Relatively fit patients with a good performance status'
         </a>
         below.)
        </p>
        <p>
         For patients who are neither frail nor fit (the majority of older adults) treatment decision-making is the most complex. Their treatment requires excellent communication and individualized care. (See
         <a class="local">
          'Less fit patients with an ECOG PS 0 or 1'
         </a>
         below.)
        </p>
        <p>
         Because of the small number of older patients enrolled in clinical trials [
         <a href="#rid7">
          7,8
         </a>
         ], good quality evidence about safety and efficacy of chemotherapy in older patients with CRC has come mainly from subgroup analyses of pooled data from large phase III clinical trials. These pooled analyses and other trials of various chemotherapy regimens in combined populations suggest that older patients have similar efficacy from chemotherapy for CRC as do younger patients, usually with only minor differences in rates of severe toxicity  (
         <a class="graphic graphic_table graphicRef76722" href="/z/d/graphic/76722.html" rel="external">
          table 7
         </a>
         ) [
         <a href="#rid6">
          6,9-13
         </a>
         ]. However, in general, patients in these trials have been fit with a good to excellent PS.
        </p>
        <p>
         Very few of these trials have attempted to use geriatric factors (such as a CGA or specific domains of the CGA such as functional status or cognitive function) to predict for severe toxicity in older adult patients receiving chemotherapy for mCRC. At least one prospective trial of different chemotherapy strategies in patients over the age of 75 suggests that baseline impaired cognition (as assessed by the Mini Mental Status Examination) and impaired autonomy (as assessed by IADL) can identify those older adult patients who are at risk for severe treatment-related toxicity, which may impact treatment selection [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2808.html" rel="external">
          "Comprehensive geriatric assessment for patients with cancer", section on 'Domains of a CGA'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14067.html" rel="external">
          "The mental status examination in adults", section on 'Cognitive screening tests'
         </a>
         .)
        </p>
        <p>
         Decision making can be aided by several tools. The information obtained from the CGA has been combined with other information, including the proposed chemotherapy regimen, hematologic and renal function, hearing impairment, and cancer type to derive models used to predict risk for severe and potentially fatal chemotherapy toxicity in the older adult population  (
         <a class="graphic graphic_table graphicRef78775" href="/z/d/graphic/78775.html" rel="external">
          table 8
         </a>
         and
         <a class="graphic graphic_table graphicRef60649" href="/z/d/graphic/60649.html" rel="external">
          table 9
         </a>
         ) [
         <a href="#rid15">
          15
         </a>
         ]. This subject is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2823.html" rel="external">
          "Systemic chemotherapy for cancer in older adults", section on 'Models predicting chemotherapy toxicity and early death'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2297942830">
         <span class="h2">
          The importance of molecular profiling
         </span>
         <span class="headingEndMark">
          —
         </span>
         Increasingly, biomarker expression is driving therapeutic decision-making in treatment of advanced cancer. Gene profiling of tumor tissue should be undertaken as quickly as possible after diagnosis of mCRC because of the significant treatment implications, both for initial systemic therapy as well as subsequent treatments. However, biomarkers that identify patients who are candidates for most of the approved agents that are active against mCRC are unknown, with several notable exceptions. (See
         <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">
          "Systemic therapy for metastatic colorectal cancer: General principles", section on 'Predictive biomarkers'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1785617606">
         <span class="h1">
          RELATIVELY FIT PATIENTS WITH A GOOD PERFORMANCE STATUS
         </span>
        </p>
        <p class="headingAnchor" id="H353907982">
         <span class="h2">
          Overview of treatment selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, we follow a similar algorithm for treatment selection in fit older patients with a good PS (Eastern Cooperative Oncology Group [ECOG] 0 to 1  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 2
         </a>
         )) as we do in younger individuals  (
         <a class="graphic graphic_algorithm graphicRef128977" href="/z/d/graphic/128977.html" rel="external">
          algorithm 1
         </a>
         ), with some exceptions. Specific issues that pertain to regimen selection in older adults are as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The doublet regimens FOLFOX (
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         plus short-term infusional
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         [FU] and
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         [LV]) and FOLFIRI (
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         plus LV and short-term infusional FU) are among the most effective for treatment of mCRC, and both are appropriate choices for first-line therapy in fit, older adult patients. The available evidence suggests that the benefits of these regimens are similar to those in younger patients, with some variations in toxicity patterns that may affect the choice of therapy:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sensory neuropathy is the most important dose-limiting toxicity of
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         ; it tends to occur once cumulative drug doses ≥700 mg/m
         <sup>
          2
         </sup>
         are reached. Initiation of FOLFIRI rather than FOLFOX may be prudent in patients with a pre-existing neuropathy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Grade 3 or 4 neutropenia and thrombocytopenia are more common with FOLFOX than with FOLFIRI  (
         <a class="graphic graphic_table graphicRef66108" href="/z/d/graphic/66108.html" rel="external">
          table 10
         </a>
         ) [
         <a href="#rid16">
          16
         </a>
         ]. Given the small increased risk of neutropenia, we often omit the FU bolus from both FOLFOX (eg, modified FOLFOX7)  (
         <a class="graphic graphic_table graphicRef55829" href="/z/d/graphic/55829.html" rel="external">
          table 11
         </a>
         ) and FOLFIRI in older patients in order to diminish treatment-related cytopenias.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nausea (13 versus 3 percent), vomiting (10 versus 3 percent), stomatitis (10 versus 1 percent), and alopecia (24 versus 9 percent) all tend to be more common with FOLFIRI than with FOLFOX [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For most patients we do not use a triplet chemotherapy regimen containing both
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         and
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         (eg, FOLFOXIRI, oxaliplatin plus irinotecan, LV, and infusional FU) over a doublet regimen containing either oxaliplatin or irinotecan. Although the triplet regimen may improve progression-free and overall survival (OS) compared with either FOLFOX or FOLFIRI in mCRC, it is also a more toxic regimen and randomized trials to date have been restricted to patients younger than 70 years. Whether these results can be extrapolated to the older adult is unclear. (See
         <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Three- versus two-drug combinations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The decision to add a biologic agent (ie,
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         or
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         /
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         , if
         <em>
          RAS
         </em>
         /
         <em>
          BRAF
         </em>
         wild-type [WT]) to cytotoxic therapy for first-line treatment must be individualized. Although fit older patients may derive similar benefits as do younger patients, these are potentially offset by the risks of serious treatment-related toxicity. In particular, we generally do not use bevacizumab in patients with stroke or myocardial infarction within the last six months or other thromboembolic disease due to the additional associated risks. (See
         <a class="local">
          'Bevacizumab and biosimilars'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         This general approach is consistent with consensus-based guidelines for treatment of mCRC in the older adult from the National Comprehensive Cancer Network [
         <a href="#rid17">
          17
         </a>
         ] and the International Society of Geriatric Oncology [
         <a href="#rid18">
          18
         </a>
         ]. A compilation of commonly used chemotherapy regimens for CRC is available. (See
         <a class="medical medical_review" href="/z/d/html/85679.html" rel="external">
          "Treatment protocols for small and large bowel cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Safety and efficacy of specific regimens in older adults
         </span>
        </p>
        <p class="headingAnchor" id="H3007152029">
         <span class="h3">
          Goals of chemotherapy and regimen selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The twin goals of systemic chemotherapy for mCRC in older individuals is the same as in younger individuals: improved symptoms and prolongation of survival. Phase III trials conducted in patients of all ages unselected for biomarkers such as
         <em>
          RAS
         </em>
         now commonly report median survivals of well over two years, and nearly 10 percent of patients are still alive at five years [
         <a href="#rid19">
          19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">
          "Systemic therapy for metastatic colorectal cancer: General principles", section on 'Systemic therapy versus supportive care'
         </a>
         .)
        </p>
        <p>
         The following sections will review the available published data that specifically address the benefits and side effects of different options for chemotherapy of mCRC in older adult patients.
        </p>
        <p class="headingAnchor" id="H639544166">
         <span class="h3">
          Immunotherapy for patients with deficient mismatch repair
         </span>
         <span class="headingEndMark">
          —
         </span>
         Largely based on the progression-free survival (PFS) benefit and more favorable toxicity profile of
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         in the phase III KEYNOTE-177 trial, first-line immunotherapy has become a preferred approach over cytotoxic chemotherapy for individuals of any age with nonoperable mCRC that is deficient in mismatch repair [
         <a href="#rid20">
          20
         </a>
         ]. The trial enrolled patients up to age 93, and approximately one-half were ≥65 years of age. In unplanned subgroup analysis, the PFS benefit was significant only in those ≤70, but a test for interaction was not provided and the confidence intervals for those &gt;70 years of age significantly overlapped those of the younger cohort. These data are presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Patients with deficient DNA mismatch repair/microsatellite unstable tumors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2916356372">
         <span class="h3">
          Tumor with proficient mismatch repair
         </span>
        </p>
        <p class="headingAnchor" id="H649096603">
         <span class="h4">
          Chemotherapy doublets
         </span>
        </p>
        <p class="headingAnchor" id="H102395802">
         <span class="h5">
          Oxaliplatin/FU combinations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The results of pooled and subgroup analyses of phase III trials, as well as phase II trials conducted exclusively in older patients suggest that standard
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         plus short-term infusional
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         (FU) and LV (FOLFOX  (
         <a class="graphic graphic_table graphicRef64504" href="/z/d/graphic/64504.html" rel="external">
          table 12
         </a>
         )) is as effective and well tolerated in fit older patients who are enrolled on clinical trials as in younger individuals [
         <a href="#rid6">
          6,11,12,21,22
         </a>
         ], although rates of side effects may be slightly higher in older patients [
         <a href="#rid11">
          11,12
         </a>
         ]. One analysis of older adult patients with CRC who were treated in the community concluded that individuals age 70 and older had higher rates of nausea, neutropenia, and neuropathy with an oxaliplatin-containing regimen as compared with those treated with a fluoropyrimidine alone [
         <a href="#rid23">
          23
         </a>
         ]. In general, efficacy rates with FOLFOX appear similar to those of
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         combined with FU and LV (FOLFIRI), but the side effect profile differs. (See
         <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'FOLFOX versus FOLFIRI'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/85679.html" rel="external">
          "Treatment protocols for small and large bowel cancer"
         </a>
         .)
        </p>
        <p>
         Additional data on combination regimens substituting
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         for short-term infusional FU in combination with
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         are discussed below. (See
         <a class="local">
          'Capecitabine-containing doublets'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1644229339">
         <span class="h5">
          Irinotecan/FU combinations
         </span>
         <span class="headingEndMark">
          —
         </span>
         In many [
         <a href="#rid24">
          24-28
         </a>
         ], but not all [
         <a href="#rid28">
          28,29
         </a>
         ] studies, combinations of
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         with infusional FU and LV (eg, FOLFIRI,  (
         <a class="graphic graphic_table graphicRef76300" href="/z/d/graphic/76300.html" rel="external">
          table 13
         </a>
         )) have been well tolerated in older patients. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The safety and efficacy in older adults as compared with younger patients was addressed in a pooled analysis of 1259 (19 percent ≥70) patients treated with
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         with either bolus FU (IFL) or short-term infusional FU (FOLFIRI) for mCRC [
         <a href="#rid25">
          25
         </a>
         ]. There were no age-related differences in response rate, time to progression, or survival (median 17 versus 18 months for older and younger patients, respectively). There were no age-related increases in diarrhea, infection, or other severe adverse events. Bolus IFL regimens have fallen out of favor because of greater toxicity (especially diarrhea) compared with infusional regimens like FOLFIRI.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The benefit and toxicity of adding
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         to FU/LV for first-line treatment of mCRC in older adults was directly addressed in a trial in which 166 patients ≥75 years of age were randomly assigned to short-term infusional FU and LV with or without irinotecan (150 mg/m
         <sup>
          2
         </sup>
         for cycles 1 and 2, with the dose increased to 180 mg/m
         <sup>
          2
         </sup>
         thereafter if tolerated) [
         <a href="#rid28">
          28
         </a>
         ]. Although the overall response rate was higher with FOLFIRI (42 versus 21 percent), this did not translate into significantly better median progression-free (7.3 versus 5.2 months) or OS (13.3 versus 14.2 months). Furthermore, rates of grade 3 or 4 toxicity were also significantly higher with irinotecan (76 versus 52 percent), with higher rates of neutropenia, febrile neutropenia, and diarrhea.
        </p>
        <p>
        </p>
        <p>
         Taken together, these studies suggest that
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         /infusional FU regimens are relatively safe for older adults. Combinations of irinotecan with
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         are discussed below. (See
         <a class="local">
          'Capecitabine-containing doublets'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2892748383">
         <span class="h5">
          Capecitabine-containing doublets
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple trials that substitute the oral fluoropyrimidine
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         for IV FU in combination with
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         (XELOX/CAPOX)  (
         <a class="graphic graphic_table graphicRef64504" href="/z/d/graphic/64504.html" rel="external">
          table 12
         </a>
         ) or
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         (XELIRI/CAPIRI) have been reported in fit older adult patients, and most indicate the safety and efficacy of this approach. However, because of concerns as to both efficacy and safety, our preference remains to deliver irinotecan with infusional FU rather than capecitabine in older patients.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          XELOX
         </strong>
         – XELOX is a reasonable substitute for FOLFOX in fit older adults. However, XELOX is not necessarily less toxic, more convenient, or less expensive than FOLFOX for the following reasons:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The appropriate dose of
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         is not well defined, at least for American patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A central venous access line is often needed for reasons other than infusional FU in patients with mCRC. Because a significant number of patients report local pain when
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         is infused via peripheral vein, many centers routinely infuse the drug centrally.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These issues are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Capecitabine doublets'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A major issue is that the appropriate dose of
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         to use in the XELOX regimen is not established. While the two European trials described above used 1000 mg/m
         <sup>
          2
         </sup>
         twice daily for 14 days, this dose is higher than most American patients can tolerate. We generally start with 850 mg/m
         <sup>
          2
         </sup>
         twice daily in fit older adult patients and start with even lower doses (750 to 800 mg/m
         <sup>
          2
         </sup>
         twice daily) in less fit individuals and in those with moderately decreased kidney function. (See
         <a class="medical medical_review" href="/z/d/html/85679.html" rel="external">
          "Treatment protocols for small and large bowel cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The efficacy and safety of XELOX in fit older adult patients has been addressed in the following trials:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A Spanish trial administered
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         (130 mg/m
         <sup>
          2
         </sup>
         on day 1) followed by
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         (1000 mg/m
         <sup>
          2
         </sup>
         twice daily for 14 of every 21 days) for first-line therapy of mCRC in 50 patients age 70 or older [
         <a href="#rid30">
          30
         </a>
         ]. The response rate was 36 percent, and median time to tumor progression and OS were 6 and 13 months, respectively. Treatment was relatively well tolerated. Grade 3 or 4 adverse events included diarrhea (22 percent), asthenia (16 percent), nausea and vomiting (14 percent), neutropenia or thrombocytopenia (6 percent), and hand-foot syndrome (4 percent). There was one treatment-related death. Comparable results were reported in an Italian study of a similar regimen in 76 patients age ≥70 [
         <a href="#rid31">
          31
         </a>
         ]. The starting dose of capecitabine was 1000 mg/m
         <sup>
          2
         </sup>
         twice daily with dose escalation permitted to 1250 mg/m
         <sup>
          2
         </sup>
         twice daily in the absence of toxicity; the initial oxaliplatin dose was 85 mg/m
         <sup>
          2
         </sup>
         , with escalation to 110 mg/m
         <sup>
          2
         </sup>
         , or even 130 mg/m
         <sup>
          2
         </sup>
         if tolerated.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The overall response rate was 41 percent, and median progression-free and OS were 9 and 14 months, respectively. Only 5 percent of patients developed grade 3 or 4 hematologic toxicity during treatment, 8 percent developed grade 3 neuropathy, and 13 percent had severe hand-foot syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The previously described randomized phase III trial of first-line
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         plus either short-term weekly infusional FU or
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         included 109 patients 70 years of age or older and 233 younger individuals [
         <a href="#rid11">
          11
         </a>
         ] (see
         <a class="local">
          'Oxaliplatin/FU combinations'
         </a>
         above). The objective response rates for XELOX in older and younger patients were 35 and 45 percent, respectively, and median OS was 17 versus 21 months; neither difference was statistically significant. Within the XELOX group, the only statistically significant toxicity difference between older and younger patients was a higher rate of grade 3 or 4 diarrhea (25 versus 8 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          XELIRI
         </strong>
         – Because of concerns as to efficacy and safety, our preference remains delivering
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         with infusional FU rather than
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         in older patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         XELIRI (
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         in combination with
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         ) produced inferior outcomes compared with FOLFIRI  (
         <a class="graphic graphic_table graphicRef64504" href="/z/d/graphic/64504.html" rel="external">
          table 12
         </a>
         ) as first-line therapy in the randomized BICC-C trial. In the original report, compared with FOLFIRI alone, capecitabine/irinotecan was associated with significantly higher rates of nausea, vomiting, diarrhea, febrile neutropenia, and dehydration as well as significantly worse PFS and a trend towards inferior median survival. (See
         <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Capecitabine doublets'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In a later subanalysis of older adults (&gt;70 years of age) versus non-older adult patients enrolled in the trial, older adult patients had significantly higher rates of asthenia and dehydration with XELIRI compared with their younger counterparts [
         <a href="#rid13">
          13
         </a>
         ]. Similar high rates of toxicity with XELIRI have been seen by others despite the use of lower starting doses of both drugs [
         <a href="#rid32">
          32,33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h4">
          Targeted therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         For fit older patients, the decision to add a biologic agent (ie,
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         or
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         /
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         , if
         <em>
          RAS
         </em>
         /
         <em>
          BRAF
         </em>
         WT) to cytotoxic therapy for first-line treatment must be individualized. Although fit older patients may derive similar benefits as do younger patients, these are potentially offset by the risks of serious treatment-related toxicity.
        </p>
        <p>
         If the decision is made to add a biologic agent, we follow the same principles as with younger patients, basing the choice of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         or an anti-EGFR agent on
         <em>
          RAS
         </em>
         /
         <em>
          BRAF
         </em>
         mutation status, contraindications to bevacizumab, and the sidedness of the primary tumor. (See
         <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'EGFR inhibitors versus bevacizumab and the influence of tumor sidedness'
         </a>
         .)
        </p>
        <p>
         An algorithmic approach to selecting initial therapy based upon these and other factors is presented in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef128977" href="/z/d/graphic/128977.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h5">
          Bevacizumab and biosimilars
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          Bevacizumab
         </a>
         is a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF). Adding bevacizumab to regimens containing a fluoropyrimidine,
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         , or
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         improves response rates, PFS, and survival. However, these advances have come with a cost of treatment-related side effects, including bleeding, hypertension, proteinuria, bowel perforation, arterial thromboembolic events (ATEs), and wound healing complications. (See
         <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Efficacy and toxicity of bevacizumab and biosimilars'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">
          "Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">
          "Cardiovascular toxicities of molecularly targeted antiangiogenic agents"
         </a>
         .)
        </p>
        <p>
         Biosimilars for
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         have also been approved by the US Food and Drug Administration [
         <a href="#rid34">
          34,35
         </a>
         ].
        </p>
        <p>
         The comparable efficacy of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         in older as compared with younger patients with mCRC has been shown in at least two separate pooled analyses [
         <a href="#rid36">
          36,37
         </a>
         ]. However, the benefits are modest and side effects, particularly ATEs, are of concern when treating older adults [
         <a href="#rid38">
          38-44
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a pooled analysis of data from four randomized trials, the magnitude of benefit for the addition of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         to fluoropyrimidine-containing chemotherapy was similar albeit modest across all age groups (&lt;65, ≥65, ≥70) [
         <a href="#rid37">
          37
         </a>
         ]. For the older age group, the median OS benefit from adding bevacizumab was only 3.3 months (median 17.4 versus 14.1 months, HR 0.79, 95% CI 0.66-0.93). Bleeding, hypertension, proteinuria, ATEs, venous thromboembolic events, wound-healing complications, fistulae, gastrointestinal perforation, and congestive heart failure were all more common in bevacizumab-treated patients. Among individuals 70 and older, the risk an arterial thrombotic event was twofold higher in the bevacizumab group (6.7 versus 3.2 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The randomized phase II PRODIGE 20 study of chemotherapy (short-term infusional FU plus LV alone or with
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         or
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         ) with or without
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         in individuals aged 75 or older, the addition of bevacizumab was associated with only a trend toward improved PFS (9.7 versus 7.8 months, HR 0.79, 95% CI 0.53-1.17) and OS (median 21.7 versus 19.8 months, HR 0.73, 95% CI 0.48-1.11) but significantly higher rate of grade 3 or 4 arterial hypertension (14 versus 6 percent) [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similarly, in the multi-center AVEX trial, 280 patients age 70 or older with previously untreated mCRC were randomly assigned to
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         (1000 mg/m
         <sup>
          2
         </sup>
         twice daily on days 1 to 14 every 21 days) with or without
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         (7.5 mg/kg on day 1 every 21 days) [
         <a href="#rid44">
          44
         </a>
         ]. Combined therapy was associated with significantly longer median PFS (the primary endpoint, 9.1 versus 5.1 months) and a non-significant trend toward longer OS (median 21 versus 17 months). However, there were significantly more events leading to treatment discontinuation in the bevacizumab arm (25 versus 15 percent), and higher rates of all-grade hemorrhage (25 versus 7 percent), hypertension (19 versus 5 percent), and venous thromboembolic events (12 versus 5 percent, grade 3 or higher, 8 versus 4 percent). There were six ATEs in the combined therapy group, compared with three with capecitabine monotherapy (4 versus 2 percent). Although rates of grade 5 (fatal) toxicities were not higher with bevacizumab (8.2 versus 11.8 percent with capecitabine alone), they were higher than expected in both groups.
        </p>
        <p>
        </p>
        <p>
         The combination of
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         and
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         is a good option for older adult patients. Caution (and informed consent) is warranted when prescribing bevacizumab in combination with chemotherapy for older adult patients with a history of atherosclerotic cardiovascular disease. The risks probably outweigh the benefits in patients with a history of stroke or myocardial infarction within the preceding 6 to 12 months, or a history of thromboembolic disease, and the drug is contraindicated in patients with severe uncontrolled hypertension. Guidelines for pretreatment risk assessment, surveillance, and treatment of hypertension in patients receiving VEGF pathway signaling inhibitors are available  (
         <a class="graphic graphic_table graphicRef73373" href="/z/d/graphic/73373.html" rel="external">
          table 14
         </a>
         and
         <a class="graphic graphic_table graphicRef63338" href="/z/d/graphic/63338.html" rel="external">
          table 15
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">
          "Cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Arterial thromboembolic events'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">
          "Cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Hypertension'
         </a>
         .)
        </p>
        <p>
         The relationship between tumor sidedness and benefit from
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         versus
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         in first-line therapy of patients with
         <em>
          RAS
         </em>
         /
         <em>
          BRAF
         </em>
         WT tumors is addressed below.
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h5">
          Cetuximab and panitumumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two monoclonal antibodies targeting the epidermal growth factor receptor (EGFR;
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         and
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         ) are active in the treatment of mCRC that lacks mutations in the
         <em>
          RAS
         </em>
         genes (WT
         <em>
          RAS
         </em>
         ). Although WT
         <em>
          RAS
         </em>
         was initially defined as the absence of mutations in codons 12 and 13 of exon 2 of the
         <em>
          KRAS
         </em>
         gene, more recent analyses suggest that exclusion of patients with other mutations in
         <em>
          KRAS
         </em>
         or
         <em>
          NRAS
         </em>
         identifies a population that is more likely to benefit from an anti-EGFR agent. (See
         <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">
          "Systemic therapy for metastatic colorectal cancer: General principles", section on 'RAS testing'
         </a>
         .)
        </p>
        <p>
         Furthermore, response to EGFR-targeted agents is highly unlikely in patients whose tumors harbor a
         <em>
          BRAF
         </em>
         V600E mutation. (See
         <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">
          "Systemic therapy for metastatic colorectal cancer: General principles", section on 'BRAF mutations'
         </a>
         .)
        </p>
        <p>
         Treatments targeting the EGFR seems to be similarly effective and safe in older as compared with younger patients [
         <a href="#rid46">
          46-51
         </a>
         ], although some reports suggest greater toxicity, especially diarrhea and acneiform skin rash [
         <a href="#rid52">
          52,53
         </a>
         ]. The largest experience comes from an analysis of patients with
         <em>
          RAS
         </em>
         WT mCRC receiving first-line doublet chemotherapy plus an anti-EGFR agent (n = 1191) versus doublet chemotherapy alone (n = 729) from seven prospective controlled clinical trials [
         <a href="#rid51">
          51
         </a>
         ]. In younger patients, the addition of first-line anti-EGFR therapy versus doublet chemotherapy significantly improved median PFS (11.2 versus 8.9, HR 0.70, 95% CI 0.60-0.82) and median OS (23.9 versus 20.3 months, HR 0.82, 95% CI 0.70-0.95), but there was only a trend towards improvement in older individuals (PFS 9.1 versus 8.7 months, HR 0.85, 95% CI 0.63-1.15; OS 24.7 versus 17.6 months, HR 0.77, 95% CI 0.58-1.04). When the analysis was limited to left side only tumors, the addition of an anti-EGFR agent significantly improved outcomes in older individuals (PFS 13.1 versus 8.5 months, HR 0.51, 95% CI 0.28-0.93; OS 26.3 versus 16.5 months, HR 0.49, 95% CI 0.28-0.85). There were no significant differences in toxicity among different age groups.
        </p>
        <p>
         Accumulating data from this trial and others suggest an association between location of the primary tumor and efficacy of anti-EGFR agents when administered for first-line therapy of mCRC. If a biologic agent is chosen for initial chemotherapy, the available data support a preference for a bevacizumab-containing rather than an anti-EGFR-containing regimen for initial treatment of right-sided tumors if a biologic agent is chosen in conjunction with cytotoxic chemotherapy, and there are no contraindications to
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         even if they are WT for
         <em>
          RAS
         </em>
         and
         <em>
          BRAF
         </em>
         . By contrast, for patients who have a left-sided WT
         <em>
          RAS
         </em>
         /
         <em>
          BRAF
         </em>
         primary tumor,
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         may provide better outcomes than bevacizumab, if a biologic agent is chosen for initial therapy. Due to the potential for detrimental impacts on survival, for patients with a right-sided tumor and a contraindication to bevacizumab, chemotherapy alone is a reasonable choice for initial therapy. These issues are all addressed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'EGFR inhibitors versus bevacizumab and the influence of tumor sidedness'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1251461221">
         <span class="h1">
          LESS FIT PATIENTS WITH AN ECOG PS 0 OR 1
         </span>
         <span class="headingEndMark">
          —
         </span>
         Less fit patients who are not frail and who have a sufficient PS are generally less able to tolerate intensive chemotherapy, although they may tolerate some chemotherapy. Options include dose-reduced FOLFOX (
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         plus short-term infusional
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         and
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         ) or CAPOX, monotherapy with a fluoropyrimidine, single-agent
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         , or, for patients without a contraindication to
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         , a combination of a bevacizumab with a fluoropyrimidine (fluorouracil [FU]/leucovorin [LV],
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         or
         <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">
          trifluridine-tipiracil
         </a>
         ). If fluoropyrimidine monotherapy is chosen, we prefer short-term infusional LV/FU (the de Gramont regimen)  (
         <a class="graphic graphic_table graphicRef65525" href="/z/d/graphic/65525.html" rel="external">
          table 16
         </a>
         ) because it is usually very well tolerated but requires central venous access and an ambulatory infusion pump. While potentially more convenient than infusional LV/FU, capecitabine monotherapy is probably more toxic.
        </p>
        <p class="headingAnchor" id="H1843507282">
         <span class="h2">
          Reduced dose FOLFOX or XELOX
         </span>
         <span class="headingEndMark">
          —
         </span>
         The benefit of an a reduced-dose oxaliplatin-containing regimen as compared with a non-oxaliplatin-containing regimen in less fit patients was directly addressed in the MRC FOCUS2 trial, described above [
         <a href="#rid4">
          4
         </a>
         ]. Briefly, 459 patients who were considered unfit for full-dose chemotherapy because of age, frailty, or both were randomly assigned, using a 2x2 factorial design, to short-term infusional FU plus LV with or without
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         , or
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         with or without oxaliplatin. Starting doses were reduced by 20 percent in all groups, with dose escalation to 100 percent of standard dose allowed at six weeks provided no grade 2 or worse toxic effects.
        </p>
        <p>
         The following were noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the comparison of FOLFOX versus short-term infusional FU and LV alone (the de Gramont regimen) FOLFOX was associated with a significantly higher objective response rate (38 versus 11 percent) and disease control rate (objective response plus stable disease, 71 versus 46 percent).There was a trend toward longer median progression-free (5.8 versus 3.5 months) and overall survival (OS; 10.7 versus 10.1 months) with
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         , which was not statistically significant. The overall risk of having a grade 3 or worse toxic effect during the first 12 weeks of treatment was slightly higher for FOLFOX (33 versus 27 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the factorial comparison of oxaliplatin-containing versus non-oxaliplatin-containing chemotherapy, use of
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         was associated with a nonsignificant trend towards better median progression-free survival (PFS; 5.8 versus 4.5 months, HR 0.84, 95% CI 0.69-1.01) but significantly higher rates of grade 3 or worse diarrhea, neurosensory toxicity, nausea, vomiting, and neutropenia compared with no use of oxaliplatin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Compared with FOLFOX, the use of
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         plus FU (XELOX) was associated with a slightly lower objective response rate (32 versus 38 percent) and overall disease control rate (objective response plus stable disease, 65 versus 71 percent), but identical PFS (5.8 months in each group), and a trend toward longer median OS that was not statistically significant (12.4 versus 10.7 months). The overall risk of having a grade 3 or worse event was higher with XELOX than FOLFOX (43 versus 33 percent). In the factorial comparison of capecitabine versus FU-containing chemotherapy, capecitabine was specifically associated with higher rates of nausea, vomiting, diarrhea, anorexia, and hand-foot syndrome.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4234024266">
         <span class="h2">
          Fluoropyrimidine monotherapy
         </span>
        </p>
        <p class="headingAnchor" id="H451295264">
         <span class="h3">
          Leucovorin-modulated FU
         </span>
         <span class="headingEndMark">
          —
         </span>
         Where fluoropyrimidine monotherapy is indicated, short-term infusional LV plus FU (LV/FU) regimens, such as the de Gramont regimen  (
         <a class="graphic graphic_table graphicRef65525" href="/z/d/graphic/65525.html" rel="external">
          table 16
         </a>
         ), are preferred over bolus regimens (which include the Mayo and Roswell park regimens [
         <a href="#rid54">
          54-57
         </a>
         ]), given the greater efficacy and tolerability, especially hematologic and gastrointestinal [
         <a href="#rid58">
          58,59
         </a>
         ]. The need for central venous access and an ambulatory infusion pump may be a limiting factor.
        </p>
        <p>
         LV enhances FU cytotoxicity by interacting with thymidylate synthase to form a stable ternary complex, prolonging inhibition of the enzyme by FU [
         <a href="#rid60">
          60
         </a>
         ]. Compared with bolus FU alone, FU/LV is associated with a twofold higher response rate (21 versus 11 percent in two meta-analyses [
         <a href="#rid61">
          61,62
         </a>
         ]), which, in one, translated into a small but statistically significant 10 percent improvement in one-year survival (47 versus 37 percent [
         <a href="#rid61">
          61
         </a>
         ]).
        </p>
        <p>
         In regimens containing LV, most American patients receive a racemic mixture of d,l-leucovorin. However, the l-isomer is the biologically active moiety, and a preparation of l-leucovorin is now commercially available in the United States (
         <a class="drug drug_general" data-topicid="10324" href="/z/d/drug information/10324.html" rel="external">
          LEVOleucovorin
         </a>
         , Fusilev). It is dosed at one-half that of d,l-leucovorin  (
         <a class="graphic graphic_table graphicRef64504" href="/z/d/graphic/64504.html" rel="external">
          table 12
         </a>
         ) and is similarly effective as the racemic mixture [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy in older as compared with younger patients
         </strong>
         – FU monotherapy is consistently tolerable in older patients, and efficacy is similar to that in younger patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Efficacy was addressed in a retrospective analysis of 629 patients over the age of 70 who were treated on 22 phase II or III trials of FU with or without modulators (including LV, interferon, or
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ) [
         <a href="#rid9">
          9
         </a>
         ]. There were 484 patients aged 70 and 75, 125 aged 75 to 80, and 20 older than 80. Response rates and survival durations among older adult patients were similar to those of younger individuals, with infusional FU regimens having a higher response rate than bolus regimens.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The results of this pooled analysis have been replicated by a number of other investigators in population-based studies, other pooled analyses, and a few phase II studies conducted exclusively in the older adult with mCRC [
         <a href="#rid64">
          64-67
         </a>
         ]. In general, older patients derive as much benefit as younger individuals, the incidence of severe neutropenia is only slightly higher in older patients, and there is no increase in other severe complications with age.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The schedule of administration impacts on toxicity.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H381137305">
         <span class="h3">
          Orally active fluoropyrimidines
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Capecitabine
         </strong>
         – Two identically designed randomized trials (602 and 605 patients, respectively) have shown similar efficacy for
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         monotherapy (1250 mg/m
         <sup>
          2
         </sup>
         twice daily for 14 of every 21 days) compared with intravenous FU/LV (the bolus Mayo regimen) for the first-line treatment of mCRC [
         <a href="#rid68">
          68,69
         </a>
         ]. However, toxicity profiles differ. In one of the trials, the incidence of grade 3 or 4 diarrhea, stomatitis, nausea, and neutropenic sepsis were significantly less in the capecitabine group; only hyperbilirubinemia and hand-foot syndrome were more common compared with FU/LV [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          Capecitabine
         </a>
         monotherapy appears to be a similarly effective, albeit potentially more toxic substitute for FU in fit older adult patients with mCRC [
         <a href="#rid4">
          4,70-75
         </a>
         ]. As examples:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a combined analysis of data from phase III trials, a higher incidence of grade 3 or 4 adverse effects (largely diarrhea, but also hand-foot syndrome) was seen in patients ≥80 years compared with the overall population (60 versus 40 percent), particularly diarrhea (31 versus 13 percent) [
         <a href="#rid70">
          70
         </a>
         ]. The specific dose of
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         was not given.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the MRC FOCUS2 trial described above, 459 patients who were considered unfit for full-dose chemotherapy because of age, frailty, or both were randomly assigned, using a 2x2 factorial design, to short-term infusional FU plus LV with or without
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         , or
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         with or without oxaliplatin [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="local">
          'Reduced dose FOLFOX or XELOX'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Starting doses were reduced by 20 percent in all groups, with dose escalation to 100 percent of standard dose allowed at six weeks provided no grade 2 or worse toxic effects. The patients in the
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         alone arm began treatment at 1000 mg/m
         <sup>
          2
         </sup>
         twice daily on days 1 to 15 every 21 days. In the factorial comparison of capecitabine versus short-term infusional FU plus LV, rates of improved global quality of life at 12 to 14 weeks were the same in both groups (56 percent).There was no evidence that substitution of FU with capecitabine had an effect on response rates (23 versus 24 percent with capecitabine- and FU-based regimens, respectively), response duration, or OS. However, compared with FU, capecitabine significantly increased the risk of a grade 3 or worse toxicity, and was specifically associated with higher rates of nausea, vomiting, diarrhea, anorexia, and hand-foot syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          Capecitabine
         </a>
         is approved in the United States for first-line treatment of mCRC, when fluoropyrimidines alone are indicated. The approved dose is 1250 mg/m
         <sup>
          2
         </sup>
         twice daily for 14 of every 21 days, and this dose may be tolerated in older individuals [
         <a href="#rid71">
          71
         </a>
         ]. However, the appropriate dose of capecitabine is not well defined, especially for American patients. As was done in the MRC FOCUS2 trial described above (and in the AVEX trial of capecitabine with or without
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         described below), many clinicians start with 1000 mg/m
         <sup>
          2
         </sup>
         rather than 1250 mg/m
         <sup>
          2
         </sup>
         twice daily, and dose-escalate to tolerance. Capecitabine also requires dose reduction in individuals with kidney impairment and in those being crossed over from infusional FU/LV [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Oral cytotoxics such as
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         require patients to make decisions regarding the safety of taking a dose in light of ongoing adverse effects such as diarrhea and hand-foot syndrome. This shifts the burden of treatment decisions from provider to the patient, which may be difficult for some older patients [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          S-1
         </strong>
         – S-1 is an oral fluoropyrimidine that includes three different agents: ftorafur (tegafur), gimeracil (5-chloro-2,4 dihydropyridine, a potent inhibitor of dihydropyrimidine dehydrogenase [DPD]), and oteracil (potassium oxonate, which inhibits phosphorylation of intestinal FU, thought responsible for treatment-related diarrhea). It is available in some countries outside of the United States.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although data are limited, S-1 appears to have a lower incidence of hand-foot syndrome than does
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          UFT
         </strong>
         – Tegafur plus uracil (UFT) is a 1:4 molar combination of ftorafur (tegafur) with uracil, which competitively inhibits the degradation of FU, resulting in sustained plasma and intratumoral concentrations [
         <a href="#rid79">
          79
         </a>
         ]. Response rates are approximately 25 percent with UFT monotherapy and 40 percent in combination with oral LV (150 mg daily) [
         <a href="#rid80">
          80
         </a>
         ]. In phase III studies, UFT plus LV has comparable efficacy and better tolerability as compared with intravenous bolus FU [
         <a href="#rid81">
          81,82
         </a>
         ]. The dose limiting toxicity is diarrhea. Myelosuppression and hand-foot syndrome are infrequent.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H765043007">
         <span class="h2">
          Bevacizumab-containing regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with mCRC who are not good candidates for
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         or
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         , and who have no contraindications to use of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         , another option is bevacizumab plus a fluoropyrimidine [
         <a href="#rid44">
          44,83-88
         </a>
         ]. If this approach is chosen, for most patient we suggest
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         plus bevacizumab rather than
         <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">
          trifluridine-tipiracil
         </a>
         (TAS-102) plus bevacizumab, given the more favorable side effect profile. Short-term infusional FU plus LV plus bevacizumab is another alternative.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          FU/LV plus
         </strong>
         <strong>
          bevacizumab
         </strong>
         – The safety and efficacy of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         plus short-term infusional
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         (FU) with
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         (LV) has been shown in several studies [
         <a href="#rid83">
          83-86,88,89
         </a>
         ]. In one of these, JCOG1018, the combination of bevacizumab plus either the de Gramont regimen or
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         monotherapy provided similar overall and PFS results to regimens that contained
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         and bevacizumab with either capecitabine or the de Gramont regimen, although the objective response rates were lower (30 versus 48 percent) [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Capecitabine
         </strong>
         <strong>
          plus
         </strong>
         <strong>
          bevacizumab
         </strong>
         – The benefit of adding
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         to
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         was shown in the phase III AVEX trial, conducted in patients 70 years of age or older [
         <a href="#rid44">
          44
         </a>
         ]. Treatment consisted of capecitabine 1000 mg/m
         <sup>
          2
         </sup>
         twice daily on days 1 to 14 of every 21-day cycles, with or without bevacizumab (7.5 mg/kg IV on day 1 of each treatment cycle). Median PFS was significantly longer with combination therapy (9.1 versus 5.1 months), although the rate of ≥grade 3 toxicity was also worse (40 versus 22 percent), especially hand-foot syndrome (16 versus 7 percent) and venous thromboembolic events (8 versus 4 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trifluridine-tipiracil
         </strong>
         <strong>
          plus
         </strong>
         <strong>
          bevacizumab
         </strong>
         – TAS-102 is an oral cytotoxic agent that consists of the nucleoside analog
         <a class="drug drug_general" data-topicid="10021" href="/z/d/drug information/10021.html" rel="external">
          trifluridine
         </a>
         (trifluorothymidine, a cytotoxic antimetabolite that, after modification within tumor cells, is incorporated into deoxyribonucleic acid (DNA) causing strand breaks) and tipiracil (a potent thymidine phosphorylase inhibitor, which inhibits trifluridine metabolism and has antiangiogenic properties as well). It is approved in the United States for treatment of mCRC previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an antiangiogenic biologic product, and a monoclonal antibody targeting the EGFR, if
         <em>
          RAS wil
         </em>
         d-type. (See
         <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'Trifluridine-tipiracil with or without bevacizumab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Two trials have directly compared the combination of TAS-102 plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         versus
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         plus bevacizumab for first-line therapy, with similar outcomes:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the TASCO1 trial, which included 153 patients with previously untreated mCRC who were ineligible for intensive therapy median PFS (the primary endpoint) was modestly but nonstatistically higher with TAS-102 (9.2 versus 7.8 months), as was median OS (22 versus 18 months, HR 0.78, 95% CI 0.55-1.10); both therapies were well tolerated, but patients receiving TAS-102 had more ≥grade 3 neutropenia, and those receiving
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         had more ≥grade 3 hand-foot syndrome and diarrhea [
         <a href="#rid87">
          87,90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A similar result was found in the much larger phase III SOLSTICE trial, which compared the same combinations in 856 previously untreated patients with mCRC who were older (42 percent), had a poor Eastern Cooperative Oncology Group (ECOG) PS or extensive comorbidity, a low tumor burden, or a preference for less intensive initial therapy [
         <a href="#rid91">
          91
         </a>
         ]. In a preliminary report, there was a trend toward better PFS (median 9.4 versus 9.3 months, HR 0.87) and OS (median 10.6 versus 9.3 months, HR 0.85) that favored TAS-102, and disease control rates were similar. However, patients receiving TAS-102 plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         also had much higher rates of ≥grade 3 neutropenia (66 versus 2 percent).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3163112236">
         <span class="h2">
          HER2-targeted therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 3 to 5 percent of CRCs have amplification of the human epidermal growth factor receptor 2
         <em>
          (HER2
         </em>
         ) oncogene or overexpress its protein product, HER2. HER2-targeted therapies are used to treat patients with HER2-overexpressing mCRC who progress on conventional chemotherapy. Further details on available agents are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'RAS wild-type, HER2 overexpressors'
         </a>
         .)
        </p>
        <p>
         Some patients with HER2-overexpressing mCRC, such as those who are not candidates for intensive therapy, may be eligible for first-line therapies targeting HER2, and this approach is supported in guidelines from the National Comprehensive Cancer Network [
         <a href="#rid92">
          92
         </a>
         ]. However, this is not our preferred approach; for most patients we reserve this for later lines of therapy. (See
         <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Not candidates for intensive therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2831465165">
         <span class="h2">
          Single-agent irinotecan
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          Irinotecan
         </a>
         is active as monotherapy. In some trials, older age is a risk factor for severe (grade 3 or 4) diarrhea [
         <a href="#rid93">
          93-95
         </a>
         ]. As an example, in a phase III comparison of weekly (125 mg/m
         <sup>
          2
         </sup>
         ) versus every three week (300 mg/m
         <sup>
          2
         </sup>
         for those over the age of 70, otherwise 350 mg/m
         <sup>
          2
         </sup>
         ) dosing of single-agent irinotecan, patients over age 70 had 1.8 times the odds of severe diarrhea than younger patients [
         <a href="#rid95">
          95
         </a>
         ]. They were also twice as likely to have severe neutropenia. The authors did not comment on rates of infection or hospitalization by age, or what proportion of the patients with grade 5 (fatal) chemotherapy toxicity were older adults.
        </p>
        <p>
         On the other hand, excessive toxicity was not seen in a trial of second-line
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         (350 mg/m
         <sup>
          2
         </sup>
         once every three weeks) in 339 patients with mCRC (72 age 70 or older) who were progressing on a fluoropyrimidine [
         <a href="#rid96">
          96
         </a>
         ]. Older patients had comparable efficacy, and toxicity (including diarrhea) was not worse as compared with younger individuals.
        </p>
        <p class="headingAnchor" id="H239521731">
         <span class="h1">
          FRAIL, SIGNIFICANT FUNCTIONAL IMPAIRMENT, POOR PERFORMANCE STATUS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals who are frail, who have a poor functional status or a poor PS (eg, Eastern Cooperative Oncology Group [ECOG] PS ≥2  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 2
         </a>
         ), Karnofsky PS &lt;60  (
         <a class="graphic graphic_table graphicRef62939" href="/z/d/graphic/62939.html" rel="external">
          table 17
         </a>
         )) usually tolerate chemotherapy poorly and have a poor short-term prognosis. For most patients, supportive care should be emphasized. However, some selected patients with mCRC who have a PS of ≥2 can be considered for trial of chemotherapy, particularly if their PS decline is cancer related.
        </p>
        <p>
         The influence of PS on the efficacy and toxicity of first-line chemotherapy was addressed in a pooled analysis of nine trials with over 6200 patients [
         <a href="#rid97">
          97
         </a>
         ]. Patients with a PS of 2 derived similar advantages with regard to efficacy from superior (ie, combination versus single agent) chemotherapy as did those with a PS of 0 to 1, but with a significantly higher risk of ≥grade 3 nausea and vomiting. The median survival for patients with a PS of 2 was less than nine months, and 12 percent died within 60 days of the start of treatment.
        </p>
        <p>
         Even some selected patients with a PS of 3 to 4 may benefit from chemotherapy, with upfront dose reduction and close monitoring for toxicity to minimize the risk for serious adverse events. As an example, in an analysis of 65 patients with mCRC and an ECOG PS 3 or 4, chemotherapy use led to a survival gain (median 6.8 versus 2.3 months for best supportive care) [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
         If a trial of chemotherapy is chosen, the choice of regimen must be individualized. For patients who are not considered appropriate candidates for intensive first-line therapy with an
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         or irinotecan-based combination regimen,
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         (LV)-modulated
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         (FU) is an appropriate option [
         <a href="#rid38">
          38
         </a>
         ]. Short-term infusional FU/LV  (
         <a class="graphic graphic_table graphicRef66108" href="/z/d/graphic/66108.html" rel="external">
          table 10
         </a>
         ) is preferred because of its more favorable toxicity profile compared with other fluoropyrimidine monotherapy schedules. (See
         <a class="local">
          'Fluoropyrimidine monotherapy'
         </a>
         above.)
        </p>
        <p>
         The addition of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         may be reasonable if there are no contraindications, but the modest survival benefit from adding bevacizumab to first-line therapy must be balanced against the potential for serious treatment-related toxicity. (See
         <a class="local">
          'Bevacizumab-containing regimens'
         </a>
         above.)
        </p>
        <p>
         If PS improves, patients initially treated with a fluoropyrimidine alone or with
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         whose PS has improved could be switched to either with an irinotecan-based or an oxaliplatin-based regimen. By contrast, supportive care alone is an option for those whose PS declines or does not improve with therapy.
        </p>
        <p class="headingAnchor" id="H569466810">
         <span class="h1">
          OPTIONS FOR LATER LINES OF THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who retain a reasonable PS and who have disease progression on the first line regimen could be considered for second line therapy. The safety and efficacy of some of these regimens in older adults is outlined in the sections below.
        </p>
        <p class="headingAnchor" id="H236988570">
         <span class="h2">
          RAS/BRAF wild type tumors not treated initially with an anti-EGFR agent
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with younger patients, for older individuals who did not receive initial EGFR-targeted therapy (ie,
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         or
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         ), an anti-EGFR agent as monotherapy or in combination with a cytotoxic chemotherapy backbone could be used for later lines of therapy. (See
         <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'No prior initial therapy with cetuximab/panitumumab'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1396397469">
         <span class="h2">
          Regorafenib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          Regorafenib
         </a>
         is an orally active inhibitor of angiogenic (including the VEGF receptors 1 to 3) receptor tyrosine kinases and other kinases that is approved in the United States for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF agent, and, if
         <em>
          KRAS
         </em>
         wild-type, an anti-EGFR therapy. Approval for mCRC was based upon the results of the CORRECT trial, which compared best supportive care plus regorafenib (160 mg orally once daily for three of every four weeks) or placebo in 760 patients with chemotherapy refractory disease, and showed a significant survival benefit for regorafenib over best supportive care alone (median 6.4 versus 5 months), albeit with little objective antitumor response [
         <a href="#rid99">
          99
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'Regorafenib'
         </a>
         .)
        </p>
        <p>
         While
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         shares many of the same side effects as
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         and
         <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">
          aflibercept
         </a>
         , including hemorrhage, bowel perforation, and hypertension, it is not yet clear whether there is an increased incidence of blood clots with this agent. (See
         <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">
          "Cardiovascular toxicities of molecularly targeted antiangiogenic agents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">
          "Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents"
         </a>
         .)
        </p>
        <p>
         There are no published data on the safety or efficacy of
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         in older adults; however, a preliminary report of a preplanned subgroup analysis of the CORRECT trial presented at the 2012 American Society of Clinical Oncology annual meeting suggested similar efficacy in patients 65 and under and those who are older [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p>
         Treatment of patients ≥70 years of age with
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         is feasible and demonstrates similar efficacy to that seen in younger patients [
         <a href="#rid101">
          101
         </a>
         ]. However, the risk of severe (grade 3 or 4) adverse events is &gt;80 percent (especially fatigue and hand-foot syndrome).
        </p>
        <p>
         The approved starting dose of 160 mg daily is probably too high for most patients, including older individuals. Treatment should be initiated at a dose of 80 mg per day (one-half the usual dose), and only escalate if the lower dose is well tolerated. Such a strategy may be particularly important in patients with borderline functional status who wish to try
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         for refractory disease while minimizing treatment-related significant side effects. (See
         <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'Regorafenib'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1698418204">
         <span class="h2">
          Trifluridine-tipiracil
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">
          Trifluridine-tipiracil
         </a>
         is an oral cytotoxic agent that consists of the nucleoside analog
         <a class="drug drug_general" data-topicid="10021" href="/z/d/drug information/10021.html" rel="external">
          trifluridine
         </a>
         (trifluorothymidine, a cytotoxic antimetabolite that inhibits thymidylate synthetase and induces DNA strand breaks) and the potent thymidine phosphorylase inhibitor tipiracil, which inhibits the metabolism of trifluridine and has antiangiogenic properties as well.
        </p>
        <p>
         In the placebo-controlled RECOURSE trial,
         <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">
          trifluridine-tipiracil
         </a>
         improved overall survival (OS) irrespective of age (&gt;65 versus ≤65 years) [
         <a href="#rid102">
          102
         </a>
         ]. The most frequently observed toxicities were gastrointestinal and hematologic, but the gastrointestinal toxicities with trifluridine-tipiracil were almost all grade 1 and 2 with few grade ≥3 events recorded. That is relevant to older patients with longstanding treatment-refractory disease who are often not tolerant of high-grade gastrointestinal toxicity.
        </p>
        <p>
         Studies also suggest that
         <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">
          trifluridine-tipiracil
         </a>
         in combination with
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         is also reasonably well tolerated in older adults [
         <a href="#rid103">
          103,104
         </a>
         ].
        </p>
        <p>
         Further details on
         <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">
          trifluridine-tipiracil
         </a>
         with or without
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         for the treatment of metastatic colorectal cancer is discussed separately. (See
         <a class="local">
          'Frail, significant functional impairment, poor performance status'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'Trifluridine-tipiracil with or without bevacizumab'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1336109249">
         <span class="h2">
          Ramucirumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="94963" href="/z/d/drug information/94963.html" rel="external">
          Ramucirumab
         </a>
         is a monoclonal antibody that binds to the VEGFR-2 extracellular domain and prevents binding of all VEGF ligands. The RAISE phase III clinical trial demonstrated that the addition of ramucirumab to FOLFIRI (
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         plus
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         and short-term infusional
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         ) improved OS compared with placebo plus FOLFIRI for second-line treatment of mCRC in patients previously treated with first-line
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         plus
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         and a fluoropyrimidine [
         <a href="#rid105">
          105
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'Ramucirumab'
         </a>
         .)
        </p>
        <p>
         The survival benefit appears to extend to individuals 65 years of age and older, according to a subgroups analysis of this trial [
         <a href="#rid106">
          106
         </a>
         ]. Furthermore, the incidence of treatment-emergent adverse reactions associated with anti-VEGF therapy were not elevated in either the ≥65 or the ≥75 age groups (although only 51 patients receiving
         <a class="drug drug_general" data-topicid="94963" href="/z/d/drug information/94963.html" rel="external">
          ramucirumab
         </a>
         were 75 or older).
        </p>
        <p class="headingAnchor" id="H1449358579">
         <span class="h2">
          Targeted therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who retain a sufficient PS and adequate levels of comorbidity, targeted therapies may be an appropriate choice for second-line therapy and beyond, if there is a potentially therapeutically actionable target, as detected by germline genomic or tumoral molecular profiling. (See
         <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'Multipanel somatic (tumor) and germline genomic testing'
         </a>
         .)
        </p>
        <p>
         As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunotherapy
         </strong>
         – For patients whose tumors have deficient mismatch repair/microsatellite instability-high or high levels of tumor mutational burden and who did not receive immunotherapy as a first-line option, immunotherapy with an immune checkpoint inhibitor that targets programmed death receptor-1 (ie,
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         , or combination therapy with nivolumab plus
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         ) is also an option for treatment at the time of disease progression on the first-line regimen. In clinical trials, objective response rates are 30 to 50 percent, and some responses are durable. (See
         <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'Microsatellite unstable/deficient mismatch repair tumors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           RAS
          </em>
         </strong>
         <strong>
          wild-type,
         </strong>
         <strong>
          <em>
           BRAF
          </em>
         </strong>
         <strong>
          mutant disease
         </strong>
         – For patients with
         <em>
          RAS
         </em>
         wild-type but
         <em>
          BRAF
         </em>
         V600E mutant mCRC that has progressed after initial chemotherapy,
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         plus
         <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">
          encorafenib
         </a>
         is an option. In an unplanned subgroup analysis of the phase III BEACON trial, efficacy of encorafenib plus cetuximab was similar in those &lt;65 and ≥65 years of age [
         <a href="#rid107">
          107
         </a>
         ]. Comparative safety was not addressed. (See
         <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'RAS wild-type, BRAF mutated tumors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other actionable alterations
         </strong>
         – Other potentially therapeutically actionable tumoral molecular alterations include human epidermal growth factor receptor 2 overexpression,
         <em>
         </em>
         tropomyosin receptor kinase (
         <em>
          TRK
         </em>
         ) fusions, and
         <em>
          RAS
         </em>
         G12C mutations. (See
         <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'RAS wild-type, HER2 overexpressors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'TRK fusion-positive tumors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          ROLE OF METASTASECTOMY
         </span>
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h2">
          Liver metastases
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite advances in chemotherapy and immunotherapy for mCRC, resection offers the best chance of long-term survival for patients with metastatic disease. The likelihood of cure is greatest in patients with liver-isolated mCRC. In surgical case series including both younger and older patients, five-year survival rates after resection range from 24 to 58 percent, averaging 40 percent  (
         <a class="graphic graphic_table graphicRef50132" href="/z/d/graphic/50132.html" rel="external">
          table 18
         </a>
         ), and perioperative mortality rates are generally less than 5 percent. (See
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy"
         </a>
         .)
        </p>
        <p>
         Similar findings were noted in a report from the LiverMetSurvey registry of 999 well-selected older adult patients 70 or older [
         <a href="#rid108">
          108
         </a>
         ]. The three-year survival rate after hepatic metastasectomy was 57 percent (similar to that of younger patients), and the 60-day perioperative mortality rate was 4 percent.
        </p>
        <p>
         Preoperative chemotherapy may facilitate the downstaging of liver metastases and render initially unresectable disease potentially resectable. (See
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'Patients with initially unresectable metastases'
         </a>
         .)
        </p>
        <p>
         However, few older adult patients have been included in trials of neoadjuvant chemotherapy. The safety and efficacy of liver resection and preoperative chemotherapy in older adult patients has been addressed in two series [
         <a href="#rid109">
          109,110
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective review included 181 liver resections that were performed in 178 consecutive patients over age 70, 19 percent of whom received neoadjuvant FOLFOX (
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         plus short-term infusional
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         [FU] and
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         [LV]) [
         <a href="#rid109">
          109
         </a>
         ]. Resection involved more than two liver segments  (
         <a class="graphic graphic_figure graphicRef81897" href="/z/d/graphic/81897.html" rel="external">
          figure 1
         </a>
         ) in 58 percent of patients and was complete in 92 percent. Perioperative mortality was 5 percent. At a median follow-up of 18 months, the actuarial rates of three-year overall and disease-free survival were 43 and 32 percent, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The second series included 70 patients aged 70 or older who underwent hepatic metastasectomy; 41 percent received neoadjuvant chemotherapy with XELOX (n = 19) or bolus FU/LV (n = 10) [
         <a href="#rid110">
          110
         </a>
         ]. In older adults, use of XELOX was associated with a significantly higher response rate than bolus FU/LV (68 versus 0 percent), and responding patients had significantly better overall and recurrence-free survival. Five-year overall survival (OS) in older adult patients was comparable to that of younger individuals treated at the same institution over the same time period (38 versus 43 percent, respectively).
        </p>
        <p>
        </p>
        <p>
         Based upon these observations, the principles of management of potentially resectable liver metastases in fit older adult patients are the same as in younger patients. However, treatment choices for neoadjuvant chemotherapy, if needed to downstage liver metastases to the point of resectability, are likely to be more critical for older patients. As noted above, whether the decreased volume of normal hepatic parenchyma seen as a consequence of normal aging predisposes older patients to chemotherapy-induced liver injury and the attendant increase in perioperative complications is unknown. However, as both
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         and
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         can induce liver injury, with steatohepatitis being associated with an increased risk of perioperative complications [
         <a href="#rid111">
          111
         </a>
         ], clinicians should exercise caution when giving oxaliplatin and irinotecan to an older patient preresection. (See
         <a class="local">
          'Challenges specific to older adults'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'Post-treatment assessment and duration of neoadjuvant therapy'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          Bevacizumab
         </a>
         inhibits wound healing. In view of this fact, and the long half-life of this agent (20 days), at least 28 days (and preferably six to eight weeks) should elapse between the last dose of bevacizumab and major surgery, including hepatectomy, if bevacizumab is included in the preoperative regimen. (See
         <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">
          "Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Bevacizumab'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h2">
          Pulmonary metastases
         </span>
         <span class="headingEndMark">
          —
         </span>
         Metastasectomy may also be considered for fit older patients with isolated pulmonary metastases. There are no large series that examine the feasibility and outcomes in older adults. However, older age has not been an independent predictor of adverse outcomes in series in which it has been examined in multivariate analysis [
         <a href="#rid112">
          112-116
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2796.html" rel="external">
          "Surgical resection of pulmonary metastases: Outcomes by histology", section on 'Colorectal cancer'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4054633676">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115274.html" rel="external">
          "Society guideline links: Colorectal cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10074443">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15412.html" rel="external">
          "Patient education: Colon and rectal cancer (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/874.html" rel="external">
          "Patient education: Colon and rectal cancer (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/860.html" rel="external">
          "Patient education: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pretreatment assessments
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Treatment decisions in older adults with metastatic colorectal cancer (mCRC) include considerations of functional status, comorbidities, and drug-specific toxicities. (See
         <a class="local">
          'Challenges specific to older adults'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Gene profiling of tumor tissue should be undertaken as quickly as possible after diagnosis of mCRC because of the significant treatment implications, both for initial systemic therapy as well as subsequent treatments. (See
         <a class="local">
          'The importance of molecular profiling'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          First-line regimen for fit adults
         </strong>
         – Our approach to initial treatment for fit older adult patients with mCRC generally mirrors that in younger patients and is outlined in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef128977" href="/z/d/graphic/128977.html" rel="external">
          algorithm 1
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach"
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with deficient mismatch repair/microsatellite instability-high tumors
         </strong>
         – Largely based on the progression-free survival benefit and more favorable toxicity profile of
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         in the phase III KEYNOTE-177 trial, first-line immunotherapy has become a preferred approach over cytotoxic chemotherapy for individuals of any age with nonoperable mCRC that is deficient in mismatch repair (dMMR). This subject is addressed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Patients with deficient DNA mismatch repair/microsatellite unstable tumors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with proficient mismatch repair
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Chemotherapy regimen
         </strong>
         – For fit older adult patients, we suggest a chemotherapy doublet (FOLFOX, XELOX, or FOLFIRI)  (
         <a class="graphic graphic_table graphicRef64504" href="/z/d/graphic/64504.html" rel="external">
          table 12
         </a>
         and
         <a class="graphic graphic_table graphicRef61781" href="/z/d/graphic/61781.html" rel="external">
          table 19
         </a>
         and
         <a class="graphic graphic_table graphicRef76300" href="/z/d/graphic/76300.html" rel="external">
          table 13
         </a>
         ) rather than fluoropyrimidine monotherapy or a triplet regimen containing both
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         and
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Given the small increased risk of neutropenia, we often omit the
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         (FU) bolus from both FOLFOX (eg, modified FOLFOX7)  (
         <a class="graphic graphic_table graphicRef63338" href="/z/d/graphic/63338.html" rel="external">
          table 15
         </a>
         ) and FOLFIRI in order to diminish treatment-related cytopenias.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Addition of biologic agent
         </strong>
         – For fit older patients, the decision to add a biologic agent (ie,
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         or
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         /
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         , if
         <em>
          RAS
         </em>
         /
         <em>
          BRAF
         </em>
         wild-type [WT]) to cytotoxic therapy for first-line treatment must be individualized. Although fit older patients may derive similar benefits as do younger patients, these are potentially offset by the risks of serious treatment-related toxicity. We do not use bevacizumab in patients with a history of stroke, myocardial infarction, or other thromboembolic disease within the preceding 6 to 12 months due to the additional associated risks.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         If the decision is made to add a biologic agent to first-line chemotherapy, we follow the same principles as with younger patients, basing the choice of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         or an anti-EGFR agent
         <em>
          on RAS
         </em>
         /
         <em>
          BRAF
         </em>
         mutation status, contraindications to bevacizumab, and the sidedness of the primary tumor. Specific recommendations are provided separately and outlined in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef128977" href="/z/d/graphic/128977.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Less fit adults with an adequate performance status
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with whose tumors have dMMR,
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         monotherapy is an alternative to first-line systemic chemotherapy. (See
         <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Patients with deficient DNA mismatch repair/microsatellite unstable tumors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For others, options include reduced dose FOLFOX or XELOX, leucovorin-modulated FU with or without
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         with or without bevacizumab,
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         alone,
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         /
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         monotherapy (for
         <em>
          RAS
         </em>
         /
         <em>
          BRAF
         </em>
         WT tumors) or
         <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">
          trifluridine-tipiracil
         </a>
         plus bevacizumab. For patients without a contraindication to bevacizumab, the survival benefit of adding bevacizumab to a first-line fluoropyrimidine must be balanced against the potential for serious treatment-related toxicity. (See
         <a class="local">
          'Less fit patients with an ECOG PS 0 or 1'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/85679.html" rel="external">
          "Treatment protocols for small and large bowel cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Frail or poor performance status
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Most individuals with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 3 or 4  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 2
         </a>
         ) cannot tolerate chemotherapy and are offered supportive care. (See
         <a class="local">
          'Frail, significant functional impairment, poor performance status'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A trial of chemotherapy is reasonable for highly selected patients with mCRC who have an ECOG PS of ≥2  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 2
         </a>
         ), particularly if their PS decline is cancer related.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment at progression
         </strong>
         – Several options are available for treatment at progression in individuals who maintain an adequate PS; limited data support efficacy and safety in older individuals. (See
         <a class="local">
          'Options for later lines of therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our approach in older, fit individuals mirrors that for younger patients and is outlined in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'Options for treatment at progression'
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI): United States Cancer Statistics. Available at: https://gis.cdc.gov/Cancer/USCS/DataViz.html (Accessed on July 10, 2018).
         </li>
         <li class="breakAll">
          The U.S. Joins Other Countries With Large Aging Populations. Available at: https://www.census.gov/library/stories/2018/03/graying-america.html#:~:text=Starting%20in%202030%2C%20when%20all,add%20a%20half%20million%20centenarians. (Accessed on June 08, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanoff HK, Goldberg RM, Pignone MP. A systematic review of the use of quality of life measures in colorectal cancer research with attention to outcomes in elderly patients. Clin Colorectal Cancer 2007; 6:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seymour MT, Thompson LC, Wasan HS, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 2011; 377:1749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohile SG, Dale W, Somerfield MR, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol 2018; 36:2326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24:4085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004; 291:2720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004; 15:1330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345:1091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sastre J, Aranda E, Massutí B, et al. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. Crit Rev Oncol Hematol 2009; 70:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arkenau HT, Graeven U, Kubicka S, et al. Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. Clin Colorectal Cancer 2008; 7:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson NA, Barrueco J, Soufi-Mahjoubi R, et al. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Cancer 2009; 115:2617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aparicio T, Jouve JL, Teillet L, et al. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol 2013; 31:1464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011; 29:3457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papamichael D, Audisio RA, Glimelius B, et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol 2015; 26:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008; 26:5721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           André T, Shiu KK, Kim TW, et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med 2020; 383:2207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Figer A, Perez-Staub N, Carola E, et al. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer 2007; 110:2666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mattioli R, Massacesi C, Recchia F, et al. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol 2005; 16:1147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cen P, Liu C, Du XL. Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer. Ann Oncol 2012; 23:1503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sastre J, Marcuello E, Masutti B, et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 2005; 23:3545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Folprecht G, Rougier P, Saltz L, et al. Irinotecan in first line therapy of elderly and non-elderly patients wtih metastatic colorectal cancer: Meta-analysis of four trials investigating 5-FU and irinotecan (abstract #3578). J Clin Oncol 2006; 24:165s.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Souglakos J, Pallis A, Kakolyris S, et al. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. Oncology 2005; 69:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           François E, Berdah JF, Chamorey E, et al. Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. Cancer Chemother Pharmacol 2008; 62:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aparicio T, Lavau-Denes S, Phelip JM, et al. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). Ann Oncol 2016; 27:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuboki Y, Mizunuma N, Ozaka M, et al. Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer. Oncol Lett 2011; 2:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feliu J, Salud A, Escudero P, et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006; 94:969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comella P, Natale D, Farris A, et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 2005; 104:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fiorentini G, Dentico P, Cantore M, et al. Capecitabine (XE) plus irinotecan (IRI) as second-line treatment (XELIRI) for metastatic colorectal cancer in elderly patients: feasibility and safety results from a phase II study (abstract # 3676). J Clin Oncol 2005; 23:289s.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosati G, Cordio S, Bordonaro R, et al. Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. Ann Oncol 2010; 21:781.
          </a>
         </li>
         <li class="breakAll">
          ZIRABEV (bevacizumab-bvzr) injection, for intravenous use. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761099s000lbl.pdf (Accessed on July 09, 2019).
         </li>
         <li class="breakAll">
          MVASI (bevacizumab-awwb) Solution for intravenous infusion. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761028s000lbl.pdf (Accessed on July 09, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurwitz HI, Tebbutt NC, Kabbinavar F, et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 2013; 18:1004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cassidy J, Saltz LB, Giantonio BJ, et al. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol 2010; 136:737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kozloff MF, Sugrue MM, Purdie DM, et al. Safety and effectiveness of bevacizumab and chemotherapy in elderly patients with metastatic colorectal cancer: Results from the BRiTE observational cohort study (abstract). J Clin Oncol 2008; 26:184s.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feliu J, Safont MJ, Salud A, et al. Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br J Cancer 2010; 102:1468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puthillath A, Mashtare T Jr, Wilding G, et al. A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. Crit Rev Oncol Hematol 2009; 71:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyerhardt JA, Li L, Sanoff HK, et al. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol 2012; 30:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsai HT, Marshall JL, Weiss SR, et al. Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study. Ann Oncol 2013; 24:1574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013; 14:1077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aparicio T, Bouché O, Taieb J, et al. Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results. Ann Oncol 2018; 29:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jehn CF, Böning L, Kröning H, et al. Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. Br J Cancer 2012; 106:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pietrantonio F, Cremolini C, Aprile G, et al. Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. Oncologist 2015; 20:1261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sastre J, Massuti B, Pulido G, et al. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. Eur J Cancer 2015; 51:1371.
          </a>
         </li>
         <li class="breakAll">
          Lonardi S, Schirripa M, Buggin F, et al. First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study (abstract). J Clin Oncol 38:2020 (suppl; abstr 4002). Abstract available online at https://meetinglibrary.asco.org/record/185499/abstract (Accessed on June 11, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papamichael D, Lopes GS, Olswold CL, et al. Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years. Eur J Cancer 2022; 163:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouchahda M, Macarulla T, Spano JP, et al. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit Rev Oncol Hematol 2008; 67:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sastre J, Grávalos C, Rivera F, et al. First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study. Oncologist 2012; 17:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7:1407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jäger E, Heike M, Bernhard H, et al. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 1996; 14:2274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buroker TR, O'Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang WS, Lin JK, Chiou TJ, et al. Randomized trial comparing weekly bolus 5-fluorouracil plus leucovorin versus monthly 5-day 5-fluorouracil plus leucovorin in metastatic colorectal cancer. Hepatogastroenterology 2000; 47:1599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15:808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein BN, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995; 75:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mini E, Trave F, Rustum YM, Bertino JR. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. Pharmacol Ther 1990; 47:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thirion P, Michiels S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22:3766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buyse M, Thirion P, Carlson RW, et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000; 356:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovoor PA, Karim SM, Marshall JL. Is levoleucovorin an alternative to racemic leucovorin? A literature review. Clin Colorectal Cancer 2009; 8:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Andre S, Sargent DJ, Cha SS, et al. 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study. Clin Colorectal Cancer 2005; 4:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Popescu RA, Norman A, Ross PJ, et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999; 17:2412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daniele B, Rosati G, Tambaro R, et al. First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study. J Clin Gastroenterol 2003; 36:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magné N, François E, Broisin L, et al. Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly: results of a 10-year experience. Am J Clin Oncol 2002; 25:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feliu J, Escudero P, Llosa F, et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol 2005; 23:3104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho C, Ng K, O'Reilly S, Gill S. Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis. Clin Colorectal Cancer 2005; 5:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ershler WB. Capecitabine use in geriatric oncology: an analysis of current safety, efficacy, and quality of life data. Crit Rev Oncol Hematol 2006; 58:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petrioli R, Pascucci A, Francini E, et al. Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors. Anticancer Drugs 2008; 19:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasetto LM, Monfardini S. The role of capecitabine in the treatment of colorectal cancer in the elderly. Anticancer Res 2006; 26:2381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hennig IM, Naik JD, Brown S, et al. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin. J Clin Oncol 2008; 26:3411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weingart SN, Brown E, Bach PB, et al. NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw 2008; 6 Suppl 3:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwakman JJM, Simkens LHJ, van Rooijen JM, et al. Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. Ann Oncol 2017; 28:1288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopec JA, Yothers G, Ganz PA, et al. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol 2007; 25:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sulkes A, Benner SE, Canetta RM. Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer. J Clin Oncol 1998; 16:3461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20:3617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douillard JY, Hoff PM, Skillings JR, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20:3605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vincenzi B, Santini D, Russo A, et al. Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial. Cancer 2009; 115:4849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23:3502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23:3706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen HX, Mooney M, Boron M, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 2006; 24:3354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Cutsem E, Danielewicz I, Saunders MP, et al. Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study. Ann Oncol 2020; 31:1160.
          </a>
         </li>
         <li class="breakAll">
          Hamaguchi T, Takashima A, Mizusawa J, et al. A randomized phase III trial of mFOLFOX7 or CapeOX plus bevacizumab versus 5-FU/l-LV or capecitabine plus bevacizumab as initial therapy in elderly patients with metastatic colorectal cancer: JCOG1018 study (RESPECT) (abstract). J Clin Oncol 2022.40.4_suppl.010. Abstract available online at https://meetinglibrary.asco.org/record/204531/abstract (Accessed on February 28, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23:3697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Cutsem E, Danielewicz I, Saunders MP, et al. First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study. Br J Cancer 2022; 126:1548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           André T, Falcone A, Shparyk Y, et al. VP11-2021: Trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study. Ann Oncol 2022; 33:ESMO #229.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network (NCCN) guidelines available lone at https://www.nccn.org/guidelines/category_1 (Accessed on March 03, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cunningham D, Pyrhönen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003; 21:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chau I, Norman AR, Cunningham D, et al. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer 2004; 91:1453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sargent DJ, Köhne CH, Sanoff HK, et al. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol 2009; 27:1948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crosara Teixeira M, Marques DF, Ferrari AC, et al. The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4. Clin Colorectal Cancer 2015; 14:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Cutsem E, Sobrero AF, Siena S, et al. Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC). J Clin Oncol 2012; 30S:ASCO #3502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aparicio T, Darut-Jouve A, Khemissa Akouz F, et al. Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 - REGOLD. J Geriatr Oncol 2020; 11:1255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015; 372:1909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           André T, Falcone A, Shparyk Y, et al. Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study. Lancet Gastroenterol Hepatol 2023; 8:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prager GW, Taieb J, Fakih M, et al. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med 2023; 388:1657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015; 16:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obermannová R, Van Cutsem E, Yoshino T, et al. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. Ann Oncol 2016; 27:2082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol 2021; 39:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adam R, Frilling A, Elias D, et al. Liver resection of colorectal metastases in elderly patients. Br J Surg 2010; 97:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Liguori Carino N, van Leeuwen BL, Ghaneh P, et al. Liver resection for colorectal liver metastases in older patients. Crit Rev Oncol Hematol 2008; 67:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamandl D, Gruenberger B, Herberger B, et al. Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients. J Surg Oncol 2009; 100:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24:2065.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onaitis MW, Petersen RP, Haney JC, et al. Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. Ann Thorac Surg 2009; 87:1684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee WS, Yun SH, Chun HK, et al. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis 2007; 22:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yedibela S, Klein P, Feuchter K, et al. Surgical management of pulmonary metastases from colorectal cancer in 153 patients. Ann Surg Oncol 2006; 13:1538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iizasa T, Suzuki M, Yoshida S, et al. Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer. Ann Thorac Surg 2006; 82:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanemitsu Y, Kato T, Hirai T, Yasui K. Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg 2004; 91:112.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2512 Version 74.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://gis.cdc.gov/Cancer/USCS/DataViz.html" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI): United States Cancer Statistics. Available at: https://gis.cdc.gov/Cancer/USCS/DataViz.html (Accessed on July 10, 2018).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.census.gov/library/stories/2018/03/graying-america.html#:~:text=Starting%20in%202030%2C%20when%20all,add%20a%20half%20million%20centenarians" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The U.S. Joins Other Countries With Large Aging Populations. Available at: https://www.census.gov/library/stories/2018/03/graying-america.html#:~:text=Starting%20in%202030%2C%20when%20all,add%20a%20half%20million%20centenarians. (Accessed on June 08, 2022).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18039423" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : A systematic review of the use of quality of life measures in colorectal cancer research with attention to outcomes in elderly patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21570111" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29782209" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16943526" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10615079" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Underrepresentation of patients 65 years of age or older in cancer-treatment trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15187053" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Participation in cancer clinical trials: race-, sex-, and age-based disparities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15319237" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11596588" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19111473" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18279579" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19382200" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23460711" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21810685" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14657227" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14657227" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25015334" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19001325" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33264544" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17963264" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15849224" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22021820" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15908665" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Irinotecan in first line therapy of elderly and non-elderly patients wtih metastatic colorectal cancer: Meta-analysis of four trials investigating 5-FU and irinotecan (abstract #3578)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16319509" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18273618" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26487578" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22866109" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16552438" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15948167" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Capecitabine (XE) plus irinotecan (IRI) as second-line treatment (XELIRI) for metastatic colorectal cancer in elderly patients: feasibility and safety results from a phase II study (abstract # 3676)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19713248" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19713248" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19713248" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23881988" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19904559" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17686822" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Safety and effectiveness of bevacizumab and chemotherapy in elderly patients with metastatic colorectal cancer: Results from the BRiTE observational cohort study (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20424611" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19081732" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22253466" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23429865" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24028813" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29045659" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22215062" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17470858" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26446234" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25963019" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25963019" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35033994" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥70 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18400508" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22363067" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2476530" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8708717" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7677801" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11149011" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Randomized trial comparing weekly bolus 5-fluorouracil plus leucovorin versus monthly 5-day 5-fluorouracil plus leucovorin in metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9053508" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7804963" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2195551" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Enhancement of the antitumor effects of 5-fluorouracil by folinic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15365073" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10972369" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19822510" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Is levoleucovorin an alternative to racemic leucovorin? A literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15663836" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10561304" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12590234" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11943888" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly: results of a 10-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11304782" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11689577" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12056707" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15860870" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16356306" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16473520" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Capecitabine use in geriatric oncology: an analysis of current safety, efficacy, and quality of life data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18043134" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16821620" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : The role of capecitabine in the treatment of colorectal cancer in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18612156" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18377852" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : NCCN Task Force Report: Oral chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28383633" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17264338" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9779725" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12202662" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12202661" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19626652" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15908660" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15867200" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16849749" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32497736" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32497736" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15738537" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35440667" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : VP11-2021: Trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : VP11-2021: Trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9807987" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9807986" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12610178" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15365570" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19255311" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25442812" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23177514" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32334940" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 - REGOLD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25970050" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36470291" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37133585" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25877855" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27573561" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33503393" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20101645" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Liver resection of colorectal metastases in elderly patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18595728" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Liver resection for colorectal liver metastases in older patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19235181" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16648507" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19463577" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17109105" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17009154" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Surgical management of pulmonary metastases from colorectal cancer in 153 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16798225" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14716804" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
